Blanket Purchase Agreement 36F79718D0422-36E79724A0012
Award Date
4/3/24
Last Date to Order
4/2/26
Federal Agency
National Acquisition Center
Awardee
Ipsen Biopharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian federal agency, to Merz Pharmaceuticals, LLC, a for-profit foreign-owned organization. The BPA is established under the GSA Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs, with a ceiling value of $12,057,300.00 and a period of performance running through March 12, 2026.
The purpose of this BPA is to provide the agency with the pharmaceutical products Ampyra and Inbrijia. No...
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026.
The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Civica Inc., a non-profit organization and manufacturer of goods. The BPA has a ceiling value of $625,000.00 and a period of performance ending on April 3, 2026.
The BPA is for the procurement of the pharmaceutical products daptomycin, lorazepam, phenylephrine, and anectine. As a BPA, this contract vehicle allows the agency to place individual task orders for these products as needed...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Day One Biopharmaceuticals, Inc. The single-award BPA has a ceiling value of $15,000,000.00 and a period of performance ending on March 7, 2026. The BPA is for the procurement of OJEMDA, though the specific products and services to be delivered are not explicitly stated in the provided information. As a BPA, this contract vehicle allows the agency to place orders for recurring...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Pfizer Inc., a global pharmaceutical manufacturer, to provide the drug Oxybryta. The single-award BPA has a ceiling value of $1,300,000.00 and a period of performance through August 29, 2024.
Pfizer, as a prime contractor, will supply the pharmaceutical product Oxybryta to support the agency's healthcare initiatives. Pfizer holds several significant Indefinite Delivery Vehicles with...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Pharming Healthcare, Inc., a foreign-owned for-profit organization. The BPA is for the procurement of the pharmaceutical products JOENJA and RUCONEST, under the General Services Administration (GSA) Schedule 61-IB (Pharmaceuticals and Drugs).
The BPA has a ceiling value of $900,000.00 and a period of performance from March 13, 2024 to March 12, 2026. No set-aside was used, and...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Health and Human Services (HHS) Office of Logistics and Acquisition Operations to IPM Scientific, Inc., a for-profit subchapter S corporation, on August 22, 2014. The BPA has an indefinite delivery, indefinite quantity (IDIQ) structure with a $0 ceiling value and a period of performance through July 31, 2024.
The BPA covers the procurement of biological materials, patient medical support services, lab/office supplies,...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to GC Biopharma USA, Inc. The contract has a ceiling value of $11,920,000.00 and a period of performance through August 5, 2025.
The BPA is for the procurement of ALYGLO products and related services. No set-aside was used for this single-award contract. As a BPA, the agreement establishes pre-negotiated terms, conditions, and pricing for the agency to issue task orders against as...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Mayne Pharma Commercial LLC, doing business as Metrics Inc. The BPA is for the procurement of halobetasol and tazaroten pharmaceuticals under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The single-award BPA has a ceiling value of $5,216,518.00 and a period of performance through May 28, 2025. As a foreign-owned, for-profit manufacturer of goods, Mayne...
This Blanket Purchase Agreement (BPA) was awarded by the Office of Logistics and Acquisition Operations, a civilian federal agency, to Southern Biotechnology Associates Inc. as a single award contract with a ceiling value of $100,000,000 and a period of performance through August 31, 2025.
The BPA is intended to procure operation and maintenance items including chemicals, blood/blood products, biological materials and media, and animal services. The broad scope of the contract suggests it may...